Cochrane · systematic review · CD013100
Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms
Huang, MW, Gibson, RC, Jayaram, MB, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
0
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 5 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Risperidone compared to electroconvulsive therapy (ECT) for schizophrenia spectrum disorders with catatonic symptoms
Population: schizophrenia spectrum disorders with catatonic symptoms
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinically important change in positive symptoms Risperidone vs electroconvulsive therapy (ECT) | no estimate extracted | 1 study · 14 participants | Ungraded |
Clinically important change in negative symptoms Risperidone vs electroconvulsive therapy (ECT) | no estimate extracted | 1 study · 14 participants | Ungraded |
Clinically important change in catatonic symptoms Risperidone vs electroconvulsive therapy (ECT) | no estimate extracted | 1 study · 14 participants | Ungraded |
Clinically important adverse drug‐induced movement disorder effects on the central nervous system (EPS, NMS, MC) Risperidone vs electroconvulsive therapy (ECT) | no estimate extracted | 1 study · 14 participants | Ungraded |
Clinically important adverse effects other than central nervous system or EPS Risperidone vs electroconvulsive therapy (ECT) | no estimate extracted | 1 study · 14 participants | Ungraded |